Dr. Daniel B. Roth, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
10 Plum St, Suite 600
New Brunswick, NJ 08901
Who else practices at this address →
Middlesex County includes mental health (21% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 828
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Tennessee, Hsc, College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
NJ license 25MA07109200 -
Ophthalmology Physician
NJ license 71092
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ocean Medical Center Brick, NJ
- Monmouth Medical Center-Southern Campus Lakewood, NJ
Medical groups
- Associated Retinal Consultants LLC (117 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 828
- Services billed
- 37,524
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 15,480 | 47 |
| Injection, ranibizumab, 0.1 mg | 2,425 | 100 |
| Imaging of retina | 2,254 | 790 |
| Injection of drug into eye | 1,816 | 295 |
| Extended exam of the back part of the eye with optic nerve drawing | 1,593 | 736 |
| Established patient complete exam of visual system | 1,551 | 645 |
| Injection, aflibercept, 1 mg | 1,112 | 117 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 1,005 | 26 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 650 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 413 | 335 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in New Brunswick, NJ | 181 |
| Prednisolone Acetate Other prescribers in New Brunswick, NJ | 140 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in New Brunswick, NJ | 88 |
| Timolol Maleate Other prescribers in New Brunswick, NJ | 43 |
| Brimonidine Tartrate Other prescribers in New Brunswick, NJ | 34 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 34 |
| Atropine Sulfate | 28 |
| Lumigan (bimatoprost) Other prescribers in New Brunswick, NJ | 18 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in New Brunswick, NJ | 16 |
| Ketorolac Tromethamine Other prescribers in New Brunswick, NJ | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 35 payments worth $24,059 in total to this clinician.
| Astellas Pharma US Inc | $23,844 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $135 |
| Apellis Pharmaceuticals, Inc. | $48.76 |
| AbbVie Inc. | $31.38 |
| Compensation for services other than consulting (speaking, faculty) | $18,000 |
|---|---|
| Consulting Fee | $4,168 |
| Travel and Lodging | $1,131 |
| Food and Beverage | $759 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $6,000 |
| Astellas Pharma US Inc Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $6,000 |
| Astellas Pharma US Inc Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $5,000 |
| Astellas Pharma US Inc Nov 26, 2025 | Consulting Fee Izervay · Ophthalmology | $2,084 |
| Astellas Pharma US Inc Mar 7, 2025 | Consulting Fee Izervay · Ophthalmology | $2,084 |
| Astellas Pharma US Inc Mar 11, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Scarsdale, NY | $1,011 |
| Astellas Pharma US Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $1,000 |
| Astellas Pharma US Inc Jun 5, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Paramus, NJ | $121 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $44,546 in research payments for these studies, mostly to the institutions running them.
- A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
Astellas Pharma Global Development - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - NRICH
Notal Vision, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.